A Sign of the Times: Nanostring Signature Series

Join us for A Sign of the Times: NanoString Signature Series – a collection of webinars focusing on Oncology Gene Expression Signatures accessible through NanoString and select CRO partners. Learn how TIS, PAM50, and LST were developed and validated, and hear from our research organizations on how the signatures are being used in the oncology field today.

Webinar Name: The rise and fall of expression levels in cancer- An introduction to NanoString’s Oncology Signatures and their applications in bulk and spatial profiling

RNA signatures are at the forefront of cancer research and are used to enhance study outcomes and accelerate the translation of findings from the bench to the clinic. NanoString has a long and rich history of providing innovative Oncology solutions, including RNA expression signatures that span immuno-oncology, breast cancer, and lymphoma. Join us for an introduction to NanoString signatures, where Dr. Ferree will provide an overview of TIS, PAM50, and LST development and validation. Signature access will be addressed, along with a glimpse into what the future holds for spatial signatures.

Webinar Name: Analytical Validation of the NanoString PanCancer IO360 Gene Expression Panel for Immuno-Oncology gene signature generation

Novel immunotherapy strategies have shown remarkable results in treating various advanced cancers but with widely variable clinical outcomes and responses in patients. A better understanding of the complex tumor-immune interactions is needed for optimizing current treatment and for developing new personalized cancer immunotherapies. In this webinar, we will highlight the analytical validation of the PanCancer IO 360 Gene Expression panel at NeoGenomics to support the panel’s use as a laboratory-developed test (LDT), in retrospective or exploratory studies. A cohort of 40 Formalin-fixed paraffin-embedded (FFPE) samples from various solid tumor indications were tested to assess the accuracy, precision, analytical specificity, and RNA input range of the PanCancer IO360 panel. Tumor Inflammation Signature (TIS) scores generated using NeoGenomics’ Tumor Inflammation Signature Algorithm App were compared against the TIS score obtained for the same set of samples at NanoString. Gene expression analysis was successful for all 770 gene targets included in the panel across all 40 samples and 100% concordance was observed between the TIS score obtained at NeoGenomics and NanoString with less than 1 TIS score unit difference. The PanCancer IO360 panel displayed 100% repeatability and reproducibility in TIS scores (≤ 0.1 TIS SD) when a set of five samples were tested in triplicate within a run and over five different runs under varying conditions, including the day of testing and varied operator and prep-station instruments. Furthermore, varied reagent lots or independent pathology assessments of specimens did not contribute significantly to any observed variance in TIS scores. In conclusion, the PanCancer IO360 panel a robust and highly reproducible tool for profiling immune-related gene expression signatures across multiple solid tumor indications.

Webinar Name: Signaling Your Interest: An Overview of Signature Access through NanoString’s Data Analysis Services (DAS) and CRO Partner Programs

NanoString offers gene expression panels and analysis services enabling the generation of signature reports for tumor inflammation signature (TIS), PAM50, lymphoma subtyping test (LST), immune-oncology and breast cancer signatures. Join us for a webinar where Dr. Church, Senior Scientist at NanoString, will introduce the solutions currently available at NanoString. She will include general panel analysis and custom analysis capabilities in her overview. Dr. Church will be joined by Leslie Abad, Global CRO Business Manager, who will review CRO partners also offering signature analysis services. This webinar will provide all the information needed to understand the signature analysis solutions and how to access them. You will leave understanding how the signatures and reports can expedite your research, how the reports can distill large amounts of data into actionable signatures, how the service eases data interpretation, how the reports provide publication ready figures, and how the service includes consultative access to NanoString scientists.

Webinar Name: A Sign of the Times: NanoString Signature Series – Utilization of Nanostring’s IO360 and TIS to Direct Spatial Investigation of the Tumor Microenvironment

Join us for A Sign of the Times: NanoString Signature Series – a collection of webinars focusing on Oncology Gene Expression Signatures accessible through NanoString and select CRO partners. Learn how TIS, PAM50, and LST were developed and validated, and hear from our research organizations on how the signatures are being used in the oncology field today.

Utilization of Nanostring’s IO360 and TIS to Direct Spatial Investigation of the Tumor Microenvironment

The complex and dynamic nature of the tumor-immune microenvironment presents challenges for identification of robust and predictive biomarkers in immuno-oncology (IO). Multiplex immunohistochemistry (mIHC) facilitates the ability to detect, phenotype, and quantify spatial relationships of cells within the tumor microenvironment (TME). Gene expression profiling allows for sensitive and high-throughput analysis of genes and signatures associated with the tumor, the immune response, and the TME, allowing examination of tumor-immune cell interactions. Attend this webinar to learn how Covance by Labcorp used these approaches to generate multiple data sets from a cohort of HNSCC tumors and evaluated the correlation of the various analyte detection methods. These complementary technologies provide useful tools in the IO biomarker toolkit.